Promising Immunotherapies Against COVID‐19

Haodong Guo,Lili Zhou,Zhenyu Ma,Zhixin Tian,Fangfang Zhou

DOI: https://doi.org/10.1002/adtp.202100044

IF: 5.003

2021-01-01

Advanced Therapeutics

Abstract:Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has led to a severe pandemic and deeply affected the livelihood of people worldwide. In response to the pandemic, researchers have been rapidly studying different aspects of COVID‐19, such as virus detection, vaccinations, and epidemiological aspects of the disease. It has been reported that SARS‐CoV‐2 can induce uncontrolled inflammation and cause a lack of antiviral response, thereby aggravating the disease. Therefore, recovery of immune functions is key to COVID‐19 treatment. Many clinical trials are exploring suitable therapies, and some progress has been made. Early administration of interferons may prevent COVID‐19 exacerbation and/or promotes recovery from the diseases. Inhibitors of inflammation can prevent cytokine storms and multi‐organ damage. Convalescent plasma containing neutralizing antibodies has played an important role in therapeutic options at the beginning of the pandemic owing to the lack of other effective methods. To aid the development of treatment options for COVID‐19, this review focuses on immunotherapies, including treatment with interferons, inhibition of pro‐inflammatory mechanisms, and the use of convalescent plasma.